Given the popularity of AAV gene therapy in ocular clinical trials, the soluble nature of IDUA, and the potential for compassionate use of AAV-IDUA in MPS1 children, our preclinical data herein provides encouraging results for a potential treatment of MPS1-associated corneal clouding. Here, IDUA is linked to mucopolysaccharidosis type 1.